Lumen Bioscience, LMN-201, C. difficile infection, REPREVE clinical trial, Phase 2 clinical trial, oral biologic, bacterial infection, infection recurrence, infectious diseases, drug development

Seattle, Washington, USA, October 21, 2026 Lumen Bioscience has announced positive Phase 2 results from its REPREVE clinical trial...